Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
DS-8201 Achieves ORR of 60.9% in Global PII in HER2-Positive Breast Cancer: Daiichi Sankyo/AZ
Daiichi Sankyo and its partner AstraZeneca said on December 11 that the investigational HER2 targeting antibody drug conjugate (ADC) DS-8201 (trastuzumab deruxtecan) hit the primary endpoint of objective response rate (ORR) at 60.9% in a multinational PII study in patients…
To read the full story
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





